(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Freshpet, BiondVax Pharmaceuticals Ltd., and Apollo Medical Holdings.

Rank Financial Asset Price Change Updated (EST)
1 Freshpet (FRPT) 45.06 14.83% 2022-09-22 14:58:18
2 BiondVax Pharmaceuticals Ltd. (BVXV) 1.07 8.65% 2022-09-22 15:08:08
3 Apollo Medical Holdings (AMEH) 41.71 6.57% 2022-09-21 21:08:09
4 Li Auto (LI) 24.40 5.63% 2022-09-22 14:50:16
5 Eli Lilly and Company (LLY) 311.80 5.17% 2022-09-22 14:47:27
6 Trip.com (TCOM) 25.65 4.99% 2022-09-22 14:51:34
7 Itau Unibanco (ITUB) 5.63 4.26% 2022-09-22 14:46:36
8 VALE (VALE) 13.67 4.11% 2022-09-22 14:53:13
9 Merck (MRK) 87.93 4.03% 2022-09-22 14:48:01
10 Rio Tinto (RIO) 55.36 4.02% 2022-09-22 14:59:38

The three biggest losers today are Novavax, Athenex, and Alterity Therapeutics Limited.

Rank Financial Asset Price Change Updated (EST)
1 Novavax (NVAX) 22.47 -13.14% 2022-09-22 14:58:54
2 Athenex (ATNX) 0.31 -12.98% 2022-09-22 01:43:14
3 Alterity Therapeutics Limited (ATHE) 0.44 -12.52% 2022-09-22 01:41:16
4 Zai Lab (ZLAB) 37.60 -12.32% 2022-09-22 14:55:35
5 Axcella Health (AXLA) 1.83 -11.17% 2022-09-22 03:23:14
6 FuboTV (FUBO) 3.92 -10.3% 2022-09-22 14:54:35
7 Caesars Entertainment (CZR) 37.56 -9.59% 2022-09-22 14:56:58
8 AMC (AMC) 7.80 -9.24% 2022-09-22 14:53:42
9 Bandwidth (BAND) 13.24 -8.56% 2022-09-22 04:23:13
10 Nikola (NKLA) 4.02 -8.33% 2022-09-22 14:50:38

Winners today

1. Freshpet (FRPT) – 14.83%

Freshpet, Inc. produces and sells natural, fresh food and treats for cats and dogs in America, Canada, Europe, and Asia. It sells products under its Freshpet and Dognation brands. The brand is also available online. Freshpet, Inc., was established in Secaucus, New Jersey in 2004.

NASDAQ ended the session with Freshpet jumping 14.83% to $45.06 on Thursday, after four successive sessions in a row of losses. NASDAQ fell 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Freshpet is 2849200 which is 181.72% above its average volume of 1011340.

Freshpet’s last close was $39.24, 75.42% under its 52-week high of $159.66.

The company’s growth estimates for the current quarter and the next is 17.6% and 80%, respectively.

Freshpet’s Revenue

Year-on-year quarterly revenue growth grew by 41.5%, now sitting on 464.25M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Freshpet’s stock is considered to be overbought (>=80).

Freshpet’s Stock Yearly Top and Bottom Value

Freshpet’s stock is valued at $45.06 at 17:32 EST, way under its 52-week high of $159.66 and way above its 52-week low of $36.02.

Freshpet’s Moving Average

Freshpet’s value is under its 50-day moving average of $47.08 and way below its 200-day moving average of $76.78.

More news about Freshpet.

2. BiondVax Pharmaceuticals Ltd. (BVXV) – 8.65%

BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company in the clinical stages. It focuses on immunomodulation treatments for infectious diseases, and mainly operates out of Israel. M-001 is the company’s product candidate. It is currently in Phase III clinical trials to treat seasonal and pandemic influenza strains. It was established in Jerusalem, Israel in 2003.

NASDAQ ended the session with BiondVax Pharmaceuticals Ltd. rising 8.65% to $1.07 on Thursday, after three consecutive sessions in a row of losses. NASDAQ dropped 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for BiondVax Pharmaceuticals Ltd. is 1338870 which is 4084.87% above its average volume of 31993.

BiondVax Pharmaceuticals Ltd.’s last close was $0.96, 72.38% under its 52-week high of $3.49.

The company’s growth estimates for the current quarter and the next is 90.4% and 59.3%, respectively.

BiondVax Pharmaceuticals Ltd.’s Stock Yearly Top and Bottom Value

BiondVax Pharmaceuticals Ltd.’s stock is valued at $1.07 at 17:32 EST, way under its 52-week high of $3.49 and way above its 52-week low of $0.89.

BiondVax Pharmaceuticals Ltd.’s Moving Average

BiondVax Pharmaceuticals Ltd.’s worth is below its 50-day moving average of $1.15 and way below its 200-day moving average of $1.39.

More news about BiondVax Pharmaceuticals Ltd..

3. Apollo Medical Holdings (AMEH) – 6.57%

Apollo Medical Holdings, Inc., an innovative technology-powered, physician-centric healthcare management company, offers medical care services. It leverages its own population health management platform and healthcare delivery platform to operate an integrated healthcare model that empowers its providers to provide care for its patients. The company offers services for patients and their families. It also provides care coordination to specialists, family members, physicians, hospitals, other inpatient sites, physician groups, health plans, and primary care doctors. It has a network of specialists, primary care doctors, and hospitalists. The company serves both patients who are primarily insured by public or private insurance such as Medicare and Medicaid. It also provides services for non-insured Californians. It was established in 1994 in Alhambra in California.

NASDAQ ended the session with Apollo Medical Holdings jumping 6.57% to $41.71 on Thursday, after two successive sessions in a row of gains. NASDAQ dropped 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for Apollo Medical Holdings is 443138 which is 82.48% above its average volume of 242831.

Apollo Medical Holdings’s last close was $41.71, 68.69% under its 52-week high of $133.23.

The company’s growth estimates for the ongoing quarter is a negative 40.5% and positive 40% for the next.

Apollo Medical Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 53.6%, now sitting on 955.17M for the twelve trailing months.

Apollo Medical Holdings’s Stock Yearly Top and Bottom Value

Apollo Medical Holdings’s stock is valued at $41.71 at 17:32 EST, way below its 52-week high of $133.23 and way higher than its 52-week low of $29.52.

Apollo Medical Holdings’s Moving Average

Apollo Medical Holdings’s worth is way under its 50-day moving average of $46.91 and way under its 200-day moving average of $47.97.

More news about Apollo Medical Holdings.

4. Li Auto (LI) – 5.63%

Through its subsidiaries, Li Auto Inc. designs, develops and manufactures new energy vehicles for the People’s Republic of China. Li ONE is a smart, six-seat electric utility vehicle with ADAS navigation and emergency break functionality. The company also provides after-sales management and technology development services. It can also purchase manufacturing equipment. The former name of the company was Leading Ideal Inc., but it changed its name in July 2020 to Li Auto Inc. Li Auto Inc. was established in 2015. It is located in Beijing, China.

NASDAQ ended the session with Li Auto jumping 5.63% to $24.40 on Thursday while NASDAQ fell 1.37% to $11,066.81.

Li Auto shares rise after the launch of 6-seat SUV Li l8, which retails for just $56,500
Premarket trading saw shares of Li Auto Inc. rise 6.2% to rebound from the four-month-old closing low. This was after China’s electric vehicle manufacturer said that it would move up its launch of the six-seat Li L8 sport utility vehicle (SUV), to September 30 because of strong demand.

Volume

Today’s last reported volume for Li Auto is 17095700 which is 58.75% above its average volume of 10768600.

Li Auto’s last close was $23.10, 44.32% under its 52-week high of $41.49.

Li Auto’s Sales

Li Auto’s sales growth is 57.5% for the current quarter and 80.7% for the next.

Li Auto’s Revenue

Year-on-year quarterly revenue growth grew by 167.5%, now sitting on 33B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Li Auto’s stock is considered to be oversold (<=20).

Li Auto’s Stock Yearly Top and Bottom Value

Li Auto’s stock is valued at $24.40 at 17:32 EST, way under its 52-week high of $41.49 and way above its 52-week low of $16.86.

Li Auto’s Moving Average

Li Auto’s worth is way under its 50-day moving average of $31.85 and way under its 200-day moving average of $28.97.

More news about Li Auto.

5. Eli Lilly and Company (LLY) – 5.17%

Eli Lilly and Company develops and markets pharmaceuticals for human use worldwide. Basaglar is available, as well as Humalog Mix 75/25 and Humalog U100. Humalog U200 and Humalog Mix 50/50. It also offers insulin lispro and insulin lispro protamine. Insulin lispro 75/25 and Humulin 70/30 and Humulin N and Humulin R for diabetes. Jardiance and Trulicity are offered for type 2. Alimta is available for the treatment of non-small-cell lung cancer. Olumiant is available for rheumatoid arthritis; Taltz can be used for plaque psoriasis and psoriatic arthritis. Cymbalta is available for depression, diabetes peripheral neuropathic, anxiety disorder and fibromyalgia; Emgality can prevent migraines and treat episodic cluster headaches; Zyprexa is for schizophrenia and bipolar I disorder; as well as bipolar maintenance. Bamlanivimab is available for COVID-19, as well as etesevimab and Bebtelovimab. Cialis can be used for benign prostatic hyperplasia and erectile dysfunction. Forteo treats osteoporosis. It has collaborations with Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc.

NYSE ended the session with Eli Lilly and Company rising 5.17% to $311.80 on Thursday while NYSE fell 0.84% to $14,116.59.

Volume

Today’s last reported volume for Eli Lilly and Company is 4112140 which is 62.6% above its average volume of 2528900.

Eli Lilly and Company’s last close was $296.48, 11.59% under its 52-week high of $335.33.

The company’s growth estimates for the present quarter and the next is 5% and 11.7%, respectively.

Eli Lilly and Company’s Revenue

Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 29.32B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Eli Lilly and Company’s stock is considered to be overbought (>=80).

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $311.80 at 17:32 EST, under its 52-week high of $335.33 and way higher than its 52-week low of $220.20.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is below its 50-day moving average of $316.71 and above its 200-day moving average of $287.26.

More news about Eli Lilly and Company.

6. Trip.com (TCOM) – 4.99%

Trip.com Group Limited is a Chinese travel agency that offers accommodation booking, travel ticketing, in- and outbound transportation, packages tours, corporate travel management and many other services. It acts as an agent in hotel-related transactions, selling airline tickets and train and long-distance ticket sales. Independent leisure travelers can also purchase bundled packages that include group, semi-group and custom-made tours and transportation options such as bus, boat, air and rental cars. The company also offers integrated transport and accommodation services, destination transportation, ticket, activity and visa transportation, as well as user support and supplier management. It also provides in-destination services and products. It also offers corporate clients business visits, incentive trips, meeting and conferences, travel data collection, analysis, industry benchmarks, cost savings analysis and travel management solutions. The company’s Corporate Travel Management System is an online platform which integrates information management with online booking, authorization and inquiry as well as travel reporting and systems. The company also offers financial and online advertising services. The company operates under the Skyscanner, Qunar and Ctrip brands. Ctrip.com International, Ltd. was the company’s previous name. In October 2019, Trip.com Group Limited became Trip.com Group Limited. Trip.com Group Limited, which was established in 1999, is located in Shanghai (People’s Republic of China).

NASDAQ ended the session with Trip.com jumping 4.99% to $25.65 on Thursday while NASDAQ slid 1.37% to $11,066.81.

Trip.com reports that hotel reservations in China are up to three times the pre-pandemic level
BEIJING — Hotel bookings in China are up more than they were in June due to the recovery in international flight bookings.

Volume

Today’s last reported volume for Trip.com is 6183280 which is 34.31% above its average volume of 4603730.

Trip.com’s last close was $24.43, 26.57% under its 52-week high of $33.27.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Trip.com’s stock is considered to be oversold (<=20).

Trip.com’s Stock Yearly Top and Bottom Value

Trip.com’s stock is valued at $25.65 at 17:33 EST, way under its 52-week high of $33.27 and way above its 52-week low of $14.29.

Trip.com’s Moving Average

Trip.com’s worth is below its 50-day moving average of $26.09 and above its 200-day moving average of $24.51.

More news about Trip.com.

7. Itau Unibanco (ITUB) – 4.26%

Itau Unibanco Holding S.A. provides a variety of financial services and products to both individuals and corporations in Brazil as well as internationally. It operates in three main segments, Retail Banking, Wholesale Banking and Activities with Market and Corporation. The company offers a variety of deposit products as well as loans, credit cards and investment and commercial banking services. It also provides financing and investment services. It also offers property and casualty products that cover loss, damage or liabilities to assets and persons. The company serves account holders and those who do not have accounts, as well as individuals, legal entities, clients with high incomes, small businesses, and microenterprises. Itau Unibanco Banco Multiplo S.A. was the company’s previous name. In April 2009, it changed its name from Itau Unibanco Holding S.A. It was founded in 1924. The company is located in Sao Paulo in Brazil. Itau Unibanco Holding S.A., a subsidiary IUPAR – Itau Unibanco Participacoes S.A.

NYSE ended the session with Itau Unibanco jumping 4.26% to $5.63 on Thursday, following the last session’s downward trend. NYSE slid 0.84% to $14,116.59, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Itau Unibanco is 42501100 which is 5.24% above its average volume of 40384000.

Itau Unibanco’s last close was $5.40, 8.32% under its 52-week high of $5.89.

The company’s growth estimates for the ongoing quarter and the next is 16.7% and 15.4%, respectively.

Itau Unibanco’s Revenue

Year-on-year quarterly revenue growth grew by 8%, now sitting on 114.1B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Itau Unibanco’s stock is considered to be oversold (<=20).

Itau Unibanco’s Stock Yearly Top and Bottom Value

Itau Unibanco’s stock is valued at $5.63 at 17:33 EST, below its 52-week high of $5.89 and way above its 52-week low of $3.60.

Itau Unibanco’s Moving Average

Itau Unibanco’s worth is way higher than its 50-day moving average of $4.79 and way higher than its 200-day moving average of $4.74.

More news about Itau Unibanco.

8. VALE (VALE) – 4.11%

Together with its subsidiaries Vale S.A. produces and sells ironore and ironore pellets to be used in steelmaking both in Brazil and abroad. Ferrous Minerals, and Base Metals are the segments that make up the company. Ferrous Minerals produces ferrous minerals, such as iron ore pellets and ferroalloys. It also provides logistical services. Base Metals produces and extracts nickel, along with its byproducts such as cobalt and precious metals. The former name of the company was Companhia Vale Do Rio Doce. In May 2009, Vale S.A. took over. Vale S.A. was established in 1942. It is located in Rio de Janeiro in Brazil.

NYSE ended the session with VALE rising 4.11% to $13.67 on Thursday, after four sequential sessions in a row of losses. NYSE slid 0.84% to $14,116.59, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for VALE is 37436700 which is 12.28% above its average volume of 33339700.

VALE’s last close was $13.13, 38.33% under its 52-week high of $21.29.

VALE’s Sales

VALE’s sales growth is a negative 17.7% for the present quarter and a decline by 4.5% for the next. The company’s growth estimates for the present quarter is a negative 24.8% and positive 44.7% for the next.

VALE’s Revenue

Year-on-year quarterly revenue growth declined by 36.8%, now sitting on 249.43B for the twelve trailing months.

VALE’s Stock Yearly Top and Bottom Value

VALE’s stock is valued at $13.67 at 17:33 EST, way below its 52-week high of $21.29 and way higher than its 52-week low of $11.16.

VALE’s Moving Average

VALE’s value is above its 50-day moving average of $13.10 and way below its 200-day moving average of $15.72.

More news about VALE.

9. Merck (MRK) – 4.03%

Merck & Co., Inc. is a global healthcare provider. The company operates in two areas: Pharmaceutical and Animal Health. It offers pharmaceutical products for human health in areas such as oncology and hospital acute care. Animal Health develops and manufactures veterinary vaccines and other health products. It also offers digitally connected traceability and identification solutions. The company serves pharmacies, government agencies, drug retailers, hospitals, as well as managed healthcare providers such as hospital benefit managers and health maintenance organizations. It also assists veterinarians, physicians, distributors of physician, and animal producers. AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. collaborate with the company to develop long-acting HIV treatments. Merck & Co., Inc. is a New Jersey-based company that was established in 1891.

NYSE ended the session with Merck jumping 4.03% to $87.93 on Thursday while NYSE fell 0.84% to $14,116.59.

Volume

Today’s last reported volume for Merck is 8099830 which is 8.84% below its average volume of 8885400.

Merck’s last close was $84.53, 11.69% below its 52-week high of $95.72.

The company’s growth estimates for the present quarter is 6.3% and a drop 10% for the next.

Merck’s Revenue

Year-on-year quarterly revenue growth grew by 28%, now sitting on 57.17B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Merck’s stock is considered to be overbought (>=80).

Merck’s Stock Yearly Top and Bottom Value

Merck’s stock is valued at $87.93 at 17:33 EST, under its 52-week high of $95.72 and way above its 52-week low of $71.12.

Merck’s Moving Average

Merck’s value is below its 50-day moving average of $89.58 and higher than its 200-day moving average of $84.41.

Previous days news about Merck

  • Merck launches new phase 3 trial of once-daily HIV treatment, to discontinue trial of once-monthly dose. According to MarketWatch on Tuesday, 20 September, " "We continue to believe in the potential of the NRTTI mechanism and we are evaluating additional candidates with the goal of helping to address unmet needs in HIV prevention," said Dr. Eliav Barr, senior vice president and heald of global clinical development, chief medical officer, Merck Research Laboratories, in a statement. "

More news about Merck.

10. Rio Tinto (RIO) – 4.02%

Rio Tinto Group is involved in the exploration, mining and processing of mineral resources around the world. It offers aluminum, copper and diamonds as well as gold, borates. titanium dioxide, salt. iron ore, lithium, and other metals. The company also has open-pit and underground mines as well as smelters and power stations. It also operates research and service centers. Rio Tinto Group, which was established in 1873, is located in London.

NYSE ended the session with Rio Tinto rising 4.02% to $55.36 on Thursday, after five sequential sessions in a row of losses. NYSE dropped 0.84% to $14,116.59, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for Rio Tinto is 3823130 which is 7.86% above its average volume of 3544360.

Rio Tinto’s last close was $53.22, 37.16% below its 52-week high of $84.69.

Rio Tinto’s Revenue

Year-on-year quarterly revenue growth declined by 10%, now sitting on 60.19B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Rio Tinto’s stock is considered to be overbought (>=80).

Rio Tinto’s Stock Yearly Top and Bottom Value

Rio Tinto’s stock is valued at $55.36 at 17:33 EST, way under its 52-week high of $84.69 and higher than its 52-week low of $53.21.

Rio Tinto’s Moving Average

Rio Tinto’s value is below its 50-day moving average of $58.53 and way below its 200-day moving average of $68.78.

More news about Rio Tinto.

Losers Today

1. Novavax (NVAX) – -13.14%

Novavax, Inc. is a biotechnology firm that focuses on vaccine development and commercialization. This company provides solutions for serious infections and addresses health care needs. Among the vaccine candidates are NVX–CoV2373, a candidate coronavirus vaccine, which is currently in 2 Phase III trials and 1 Phase IIb trial. NanoFlu is a candidate nanoparticle seasonal quadrivalent flu vaccine that is currently in Phase 3. ResVax is a candidate respiratory syncytialvirus (RSV), fusion (F), protein nanoparticle vaccine. The company is currently developing RSV F vaccine, which is being tested in Phase II clinical trials for adults aged 60 years or older. It also has a Phase I clinical trial in pediatrics. Takeda Pharmaceutical Company Limited has signed a cooperation agreement for the production, commercialization, and development of NVXCoV2373 (a COVID-19 candidate vaccine). Novavax, Inc., was founded in 1987. It is located in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax falling 13.14% to $22.47 on Thursday, after five sequential sessions in a row of losses. NASDAQ dropped 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around negative trend trading session today.

Novavax shares continue to plummet after J.P. Morgan becomes bearish on the expectation of further guidance reductions
Novavax Inc. shares plunged 7.1% Thursday morning, after J.P. Morgan, who was citing increased revenue guidance, decided to end the J.P. Morgan deal with the Novavax Inc. maker of COVID-19 vaccine Nuvaxovid.

Volume

Today’s last reported volume for Novavax is 10142200 which is 67.22% above its average volume of 6065110.

Novavax’s last close was $25.87, 90.08% under its 52-week high of $260.69.

The company’s growth estimates for the current quarter and the next is 215.8% and 247.6%, respectively.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 57.4%, now sitting on 1.4B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be overbought (>=80).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $22.47 at 17:34 EST, way below its 52-week low of $28.25.

Novavax’s Moving Average

Novavax’s value is way under its 50-day moving average of $45.89 and way below its 200-day moving average of $75.51.

More news about Novavax.

2. Athenex (ATNX) – -12.98%

Athenex, Inc. is a biopharmaceutical firm that focuses on the development, commercialization, and discovery of medicines for cancer treatment. The company operates in three distinct segments, the Oncology Innovation Platform and Global Supply Chain Platform. Oral Paclitaxel is the company’s Orascovery candidate. It is currently in phase III for metastatic breast carcinoma, along with various clinical trials in advanced malignancies, gastric cancer, and other cancers. Oral Irinotecan is also in Phase I for treatment of metastatic colorectal, glioblastoma and lung cancer. Oral Docetaxel, Encequidar and Oral Docetaxel are Oral Docetaxel, an effective anticancer drug. They also include Oral Topotecan, Encequidar and Oral Topotecan, an oral anticancer drug in Phase 1 clinical trials to treat breast, cervical, head, neck, and ovarian cancers. Oral Eribulin, Encequidar and Oral Eribulin, intravenous anticancer drugs to treat breast and liposarcoma and certain patients. The company also offers Src Kinase products candidates, including Tirbanibulin creams for skin and actinic disorders, Tirbanibulin Oral to treat solid and liquid tumors and KX2-361 to treat glioblastoma multifocale. It is also developing dual absorption boosters that inhibit both the P-gp and cytochrome P450 enzymes in the gastrointestinal tract. T Cell Receptor Engineering T Cell provides a cell-based immunotherapy and PT01 (Pegtomarginase) an arginine-deprivation therapy product. The former name of the company was Kinex Pharmaceuticals LLC. In August 2015, Athenex, Inc. became Athenex, Inc. Athenex, Inc., was founded in 2003. It is located in Buffalo, New York.

NASDAQ ended the session with Athenex sliding 12.98% to $0.31 on Thursday while NASDAQ fell 1.37% to $11,066.81.

Volume

Today’s last reported volume for Athenex is 1560000 which is 27.85% below its average volume of 2162320.

Athenex’s last close was $0.31, 90.96% under its 52-week high of $3.42.

Athenex’s Sales

Athenex’s sales growth is 21.7% for the present quarter and 18.8% for the next. The company’s growth estimates for the current quarter and the next is 54.5% and 86.3%, respectively.

Athenex’s Revenue

Year-on-year quarterly revenue growth grew by 43.8%, now sitting on 120.99M for the twelve trailing months.

Athenex’s Stock Yearly Top and Bottom Value

Athenex’s stock is valued at $0.31 at 17:34 EST, way under its 52-week high of $3.42 and above its 52-week low of $0.30.

Athenex’s Moving Average

Athenex’s value is way below its 50-day moving average of $0.55 and way under its 200-day moving average of $0.78.

More news about Athenex.

3. Alterity Therapeutics Limited (ATHE) – -12.52%

Alterity Therapeutics Limited develops, researches and produces therapeutic drugs to treat Parkinsonian disease in Australia. The company has ATH434 as its lead drug candidate, which is currently in Phase 1 clinical trials for Parkinson’s Disease. The company is currently developing PBT2 as an antimicrobial agent. The company used to be known as Prana Biotechnology Limited. In April 2019, Alterity Therapeutics Limited was established. It was established in 1997. The company is located in Melbourne, Australia.

NASDAQ ended the session with Alterity Therapeutics Limited dropping 12.52% to $0.44 on Thursday while NASDAQ slid 1.37% to $11,066.81.

Volume

Today’s last reported volume for Alterity Therapeutics Limited is 371522 which is 236.96% above its average volume of 110256.

Alterity Therapeutics Limited’s last close was $0.44, 68.12% below its 52-week high of $1.38.

Alterity Therapeutics Limited’s Revenue

Year-on-year quarterly revenue growth grew by 25.3%, now sitting on 4.82M for the twelve trailing months.

Alterity Therapeutics Limited’s Stock Yearly Top and Bottom Value

Alterity Therapeutics Limited’s stock is valued at $0.44 at 17:34 EST, way under its 52-week high of $1.38 and higher than its 52-week low of $0.40.

Alterity Therapeutics Limited’s Moving Average

Alterity Therapeutics Limited’s value is way under its 50-day moving average of $0.60 and way under its 200-day moving average of $0.73.

More news about Alterity Therapeutics Limited.

4. Zai Lab (ZLAB) – -12.32%

Zai Lab Limited is a company that develops and markets therapies for oncology and autoimmune disorders. It also has a focus in neuroscience. Zejula is a once daily small-molecule, polymerase 1/2 inhibitor. Optune delivers treatment fields to tumors. NUZYRA treats skin structures and acute bacterial infections. Qinlock can treat gastrointestinal tumors. Odronextamab is also developed to treat diffuse large B cell lymphoma and other types of B-celllymphomas. Repotrectinib (a tyrosinekinase inhibitor) targets ROS1 or TRK A/B/C for patients who have been treated with TKI. Margetuximab can be used to treat breast cancer and stomach cancer. Adagrasib treats KRAS G12C-mutated NSCLC. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited, a Shanghai-based company was established in 2013.

NASDAQ ended the session with Zai Lab dropping 12.32% to $37.60 on Thursday while NASDAQ dropped 1.37% to $11,066.81.

Volume

Today’s last reported volume for Zai Lab is 860714 which is 56.72% above its average volume of 549182.

Zai Lab’s last close was $42.89, 65.95% below its 52-week high of $125.97.

Zai Lab’s Sales

Zai Lab’s sales growth is 56.6% for the current quarter and 37.7% for the next. The company’s growth estimates for the current quarter and the next is 66.7% and 40.9%, respectively.

Zai Lab’s Revenue

Year-on-year quarterly revenue growth grew by 132.4%, now sitting on 170.93M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Zai Lab’s stock is considered to be overbought (>=80).

Zai Lab’s Stock Yearly Top and Bottom Value

Zai Lab’s stock is valued at $37.60 at 17:34 EST, way under its 52-week high of $125.97 and way higher than its 52-week low of $22.51.

Zai Lab’s Moving Average

Zai Lab’s worth is way below its 50-day moving average of $43.73 and way below its 200-day moving average of $44.95.

More news about Zai Lab.

5. Axcella Health (AXLA) – -11.17%

Axcella Healthcare Inc. is a US-based clinical stage biotechnology firm. The company treats complicated diseases, and improves the health of patients by using endogenous metabolism modulator compositions. AXA1665 is the company’s leading product candidate for overt hepatic enzymephalopathy. AXA1125 treats non-alcoholic statohepatitis. AXA4010 is a potential hematology candidate. AXA2678 is a possible muscle candidate. The original name of the company was Newco LS16, Inc., but it changed its name to Axcella Health Inc. on June 2016. Axcella Healthcare Inc. was established in 2008. It is located in Cambridge, Massachusetts.

NASDAQ ended the session with Axcella Health falling 11.17% to $1.83 on Thursday while NASDAQ dropped 1.37% to $11,066.81.

Volume

Today’s last reported volume for Axcella Health is 68903 which is 7.19% above its average volume of 64277.

Axcella Health’s last close was $1.83, 58.41% under its 52-week high of $4.40.

The company’s growth estimates for the present quarter and the next is 7.1% and 7.3%, respectively.

Axcella Health’s Stock Yearly Top and Bottom Value

Axcella Health’s stock is valued at $1.83 at 17:35 EST, way under its 52-week high of $4.40 and way higher than its 52-week low of $1.35.

Axcella Health’s Moving Average

Axcella Health’s value is way below its 50-day moving average of $2.19 and way under its 200-day moving average of $2.08.

More news about Axcella Health.

6. FuboTV (FUBO) – -10.3%

FuboTV Inc. provides live streaming for entertainment, sports and news content throughout the United States. Customers can access the fuboTV platform via streaming devices as well as SmartTVs and computers. New York is the headquarters of this company.

NYSE ended the session with FuboTV falling 10.3% to $3.92 on Thursday, after two successive sessions in a row of gains. NYSE fell 0.84% to $14,116.59, after two successive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for FuboTV is 9840660 which is 39.54% below its average volume of 16277100.

FuboTV’s last close was $4.37, 87.55% under its 52-week high of $35.10.

FuboTV’s Sales

FuboTV’s sales growth is 102.2% for the present quarter and 99.7% for the next. The company’s growth estimates for the ongoing quarter is a negative 18.6% and positive 5.9% for the next.

FuboTV’s Revenue

Year-on-year quarterly revenue growth grew by 119.9%, now sitting on 638.35M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

FuboTV’s stock is considered to be overbought (>=80).

FuboTV’s Stock Yearly Top and Bottom Value

FuboTV’s stock is valued at $3.92 at 17:35 EST, way below its 52-week high of $35.10 and way higher than its 52-week low of $2.49.

FuboTV’s Moving Average

FuboTV’s value is above its 50-day moving average of $3.60 and way under its 200-day moving average of $13.77.

More news about FuboTV.

7. Caesars Entertainment (CZR) – -9.59%

Caesars Entertainment, Inc. is a US-based gaming and hospitality business. It operates casinos that offer poker, keno and other online games; restaurants, bars and nightclubs as well as hotels and entertainment venues. The company also offers staffing, management, accessories, souvenirs and decorative items via retail shops; as well as online sports betting, iGaming, and other services. The company managed, owned and leased 52 properties across 16 US states. These included approximately 55,700 slots, video lottery terminals and e-tables. There were also 2,900 table games and 47,700 hotel rooms. Caesars Entertainment, Inc., was established in Reno, Nevada in 1937.

NASDAQ ended the session with Caesars Entertainment dropping 9.59% to $37.56 on Thursday, after two consecutive sessions in a row of losses. NASDAQ fell 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Caesars Entertainment is 6575230 which is 90.71% above its average volume of 3447630.

Caesars Entertainment’s last close was $41.54, 65.33% under its 52-week high of $119.81.

Caesars Entertainment’s Sales

Caesars Entertainment’s sales growth is 5.3% for the ongoing quarter and 7.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 114.5% and 98%, respectively.

Caesars Entertainment’s Revenue

Year-on-year quarterly revenue growth grew by 27.9%, now sitting on 10.07B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Caesars Entertainment’s stock is considered to be overbought (>=80).

Caesars Entertainment’s Stock Yearly Top and Bottom Value

Caesars Entertainment’s stock is valued at $37.56 at 17:35 EST, way under its 52-week high of $119.81 and higher than its 52-week low of $35.10.

Caesars Entertainment’s Moving Average

Caesars Entertainment’s worth is way below its 50-day moving average of $44.98 and way below its 200-day moving average of $64.13.

More news about Caesars Entertainment.

8. AMC (AMC) – -9.24%

Through its subsidiaries, AMC Entertainment Holdings, Inc. engages in theatrical exhibitions. It owns or operates theatres in Europe and the United States. It operated approximately 950 theaters and 10600 screens as of March 1, 2022. It was established in 1920. The headquarters are in Leawood in Kansas.

NYSE ended the session with AMC sliding 9.24% to $7.80 on Thursday while NYSE slid 0.84% to $14,116.59.

AMC stock forecast: AMC Entertainment sinks after fed rate hike triggers late-session crash
AMC shares fell another 1.3% after a slow summer and ended the trading session at $8.60.

Volume

Today’s last reported volume for AMC is 24900700 which is 44.11% below its average volume of 44556500.

AMC’s last close was $8.60, 81.28% below its 52-week high of $45.95.

The company’s growth estimates for the present quarter and the next is 73.2% and 52.3%, respectively.

AMC’s Revenue

Year-on-year quarterly revenue growth grew by 429.8%, now sitting on 3.17B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

AMC’s stock is considered to be overbought (>=80).

AMC’s Stock Yearly Top and Bottom Value

AMC’s stock is valued at $7.80 at 17:35 EST, under its 52-week low of $7.89.

AMC’s Moving Average

AMC’s value is way under its 50-day moving average of $14.85 and way below its 200-day moving average of $17.36.

Previous days news about AMC

  • AMC stock forecast: AMC entertainment rises despite another slow weekend at the box office. According to FXStreet on Tuesday, 20 September, "On Monday, shares of AMC rose higher by 2.23% and closed the first trading session of the week at a price of $9.18. ", "A lack of blockbusters certainly has a lot to do with it, and even though Hollywood has promised to deliver some for the holiday season, that doesn’t help AMC much right now. "
  • AMC stock forecast: AMC entertainment slips lower as meme stocks continue to struggle. According to FXStreet on Wednesday, 21 September, "On Tuesday, shares of AMC slipped by 5.12% and closed the trading session at a price of $8.71. "

More news about AMC.

9. Bandwidth (BAND) – -8.56%

Bandwidth Inc. operates as a cloud-based software-powered communications platform-as-a-service (CPaaS) provider in the United States. It operates two business segments: CPaaS, and Other. The platform allows enterprises to build, scale and manage voice or messaging services on various mobile apps or connected devices. SIP trunking and data resale are also offered by the company. Hosted voice over Internet protocol (HVOIP) services can be provided as well. The company serves many businesses including large corporations, communication service providers, conferencing provider, call centers, small- and medium-sized companies as well emerging tech companies. Bandwidth Inc. was established in 2000. It is located in Raleigh, North Carolina.

NASDAQ ended the session with Bandwidth falling 8.56% to $13.24 on Thursday, after five consecutive sessions in a row of losses. NASDAQ fell 1.37% to $11,066.81, after two successive sessions in a row of losses, on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Bandwidth is 781361 which is 54.26% above its average volume of 506491.

Bandwidth’s last close was $13.24, 86.82% below its 52-week high of $100.49.

Bandwidth’s Sales

Bandwidth’s sales growth is 10.8% for the ongoing quarter and 12.9% for the next. The company’s growth estimates for the present quarter and the next is a negative 118.8% and a negative 92%, respectively.

Bandwidth’s Revenue

Year-on-year quarterly revenue growth grew by 15.8%, now sitting on 508.79M for the twelve trailing months.

Bandwidth’s Stock Yearly Top and Bottom Value

Bandwidth’s stock is valued at $13.24 at 17:35 EST, way below its 52-week high of $100.49 and higher than its 52-week low of $13.21.

Bandwidth’s Moving Average

Bandwidth’s worth is way under its 50-day moving average of $16.74 and way below its 200-day moving average of $33.91.

More news about Bandwidth.

10. Nikola (NKLA) – -8.33%

Nikola Corporation is a technology integrator and innovator that develops energy and transport solutions. The company operates via two business units: Truck and Energy. The truck business unit designs and sells semi-trucks that are battery-electric or hydrogen-electric. Energy is responsible for developing and constructing a network hydrogen fueling stations. It also offers charging options for FCEV, BEV, and other customers. In collaboration with suppliers and business partners, the company also builds, integrates and commissions vehicles. Nikola Corporation has its headquarters in Phoenix, Arizona.

NASDAQ ended the session with Nikola dropping 8.33% to $4.02 on Thursday while NASDAQ dropped 1.37% to $11,066.81.

Volume

Today’s last reported volume for Nikola is 19102100 which is 66.26% above its average volume of 11489100.

Nikola’s last close was $4.38, 71.85% under its 52-week high of $15.56.

The company’s growth estimates for the current quarter and the next is a negative 40% and a negative 45.5%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Nikola’s stock is considered to be overbought (>=80).

Nikola’s Stock Yearly Top and Bottom Value

Nikola’s stock is valued at $4.02 at 17:35 EST, below its 52-week low of $4.41.

Nikola’s Moving Average

Nikola’s value is way under its 50-day moving average of $6.00 and way below its 200-day moving average of $7.44.

More news about Nikola.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here